Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness. Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 and HYPER-H21-2 provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings.”
To view the full article, visit https://cnw.fm/auPYf
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.